WallStreetZen

NYSE: NVO
Novo Nordisk A S Earnings & Revenue

NVO past earnings growth

How has NVO's earnings growth performed historically?
Company
15.21%
Industry
16.58%
Market
104.53%
NVO's earnings have grown slower (7.72% per year) than the US Biotechnology industry average (16.77%)
Performance
NVO's earnings have grown slower (7.72% per year) than the US market average (31.1%)
Performance
NVO's earnings growth is accelerating - its growth over the last year (15.21%) is above its 5-year compound annual rate (7.72%)
Performance

NVO past revenue growth

How has NVO's revenue growth performed historically?
Company
8.71%
Industry
813.92%
Market
41.42%
NVO's revenue has grown slower (4.77% per year) than the US Biotechnology industry average (160.74%)
Performance
NVO's revenue has grown slower (4.77% per year) than the US market average (19.51%)
Performance
NVO's revenue growth is accelerating - its growth over the last year (8.71%) is above its 5-year compound annual rate (4.77%)
Performance

NVO earnings and revenue history

Current Revenue
$20.8B
Current Earnings
$7.1B
Current Profit Margin
34.1%

NVO Return on equity

Current Company
71.9%
Current Industry
-10.9%
Current Market
23.1%
NVO's Return on Equity (71.9%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

NVO Return on assets

Current Company
30.4%
Current Industry
-8.1%
NVO is generating higher Return on Assets (30.4%) than the US Biotechnology industry average (-4.27%)
Performance

NVO Return on capital employed

Current Company
66.95%
Current Industry
1.2%

Novo Nordisk A S Earnings & Revenue FAQ

What were NVO's earnings last quarter?

Novo Nordisk A S (NYSE: NVO) reported Q2 2021 earnings per share (EPS) of $0.84, up 22.74% year over year. Total Novo Nordisk A S earnings for the quarter were $1.94 billion. In the same quarter last year, Novo Nordisk A S's earnings per share (EPS) was $0.69.

What was NVO's earnings growth in the past year?

As of Q4 2021, Novo Nordisk A S's earnings has grown 15.21% year over year. This is 1.37 percentage points lower than the US Biotechnology industry earnings growth rate of 16.58%. Novo Nordisk A S's earnings in the past year totalled $7.06 billion.

What was NVO's revenue last quarter?

Novo Nordisk A S (NYSE: NVO) reported Q2 2021 revenue of $5.29 billion up 16.63% year over year. In the same quarter last year, Novo Nordisk A S's revenue was $4.53 billion.

What was NVO's revenue growth in the past year?

As of Q4 2021, Novo Nordisk A S's revenue has grown 8.71% year over year. This is 805.21 percentage points lower than the US Biotechnology industry revenue growth rate of 813.92%. Novo Nordisk A S's revenue in the past year totalled $20.69 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.